Skip to Main Content

Top of the morning to you. Another busy day is unfolding here on the Pharmalot campus, where we are mulling over our cluttered calendar and plotting our next moves. No doubt, you can relate. After all, this is only the middle of the week and there is so much to be done. This calls, as you may imagine, for a hot cup of stimulation. Our choice today is bourbon pecan. Feel free to join us. Meanwhile, here are some tidbits. The world is a busy place, yes? Hope you make your way today. …

A U.S. Food and Drug Administration advisory panel is scheduled to vote Wednesday whether Covid-19 vaccines from Pfizer and BioNTech and from Moderna should be cleared for use in children as young as 6 months old, The Wall Street Journal writes. A positive recommendation would likely lead soon to expanding the U.S. Covid-19 vaccination campaign to the 19.6 million children 6 months to 5 years of age, the last group of people in the U.S. waiting for shots. The Moderna shot is up for FDA authorization in children 6 months to 5 years, while the Pfizer vaccine is under review for children 6 months to 4 years. STAT will be live blogging, and here are some issues to watch.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment